Home » Trials » SLCTR/2026/032


Effect of Wearable Wrist Blood Pressure Monitoring Compared to Home and Office Blood Pressure Monitoring on Systolic Blood Pressure Control Among Adults With Hypertension in Sri Lanka: A Pilot Randomized Controlled Trial

-

SLCTR Registration Number

SLCTR/2026/032


Date of Registration

20 Nov 2026

The date of last modification

Nov 20, 2026



Application Summary


Scientific Title of Trial

Effect of Wearable Wrist Blood Pressure Monitoring Compared to Home and Office Blood Pressure Monitoring on Systolic Blood Pressure Control Among Adults With Hypertension in Sri Lanka: A Pilot Randomized Controlled Trial


Public Title of Trial

Comparing Wrist-Worn, Home, and Clinic Blood Pressure Monitoring to Improve Blood Pressure Control in Adults With Hypertension in Sri Lanka


Disease or Health Condition(s) Studied

Hypertension


Scientific Acronym

WATCH-BP Trial


Public Acronym

WATCH-BP Trial


Brief title

WATCH-BP: Wrist-Worn Blood Pressure Monitoring for Hypertension Control


Universal Trial Number

U1111-1347-0653


Any other number(s) assigned to the trial and issuing authority

EC-26-079 (Ethics Review Committee, Faculty of Medicine, Colombo)


Trial Details


What is the research question being addressed?

Among adults with hypertension in Sri Lanka, does wearable wrist blood pressure monitoring, compared with home blood pressure monitoring or conventional office blood pressure monitoring, improve systolic blood pressure control over three months?


Type of study

Interventional


Study design

Allocation

Randomized controlled trial


Masking

Masking not used


Control

Standard therapy/practice


Assignment

Parallel


Purpose

Device feasibility


Study Phase

Not Applicable


Intervention(s) planned

1.Study site – Outpatient medical clinics of the National Hospital of Sri Lanka (NHSL), Colombo.

2.Details of randomization

• Method: Cluster randomization of medical clinics in a 1:1:1 ratio to the three study arms.

Arm 1 - Wrist-worn blood pressure monitoring system Arm 2 - Home BP group Arm 3 - Office BP group

• Unit of randomization: Medical clinic.

• Sequence generation: Computer-generated random allocation sequence prepared by an independent investigator not involved in recruitment. • Allocation concealment: Individual-level allocation concealment is not applicable, as clinics are randomized before participant recruitment. Participants are then recruited consecutively from each allocated clinic.

3.Intervention The intervention consists of a wrist-worn blood pressure monitoring system integrated within a wearable device. The blood pressure measurement is based on an oscillometric technique adapted for the wrist, utilizing an inflatable airbag cuff embedded within the wrist strap. During measurement, the airbag automatically inflates to apply controlled external pressure over the radial artery at the wrist. As the cuff pressure is gradually released, the device detects arterial pulsations (oscillations) within the cuff. These oscillometric signals are processed using proprietary algorithms to estimate systolic and diastolic blood pressure values. The measurement process is fully automated, requiring minimal user input, and is designed to allow repeated measurements in real-world, ambulatory conditions. The system enables both spot measurements initiated by the user and scheduled measurements at predefined intervals, facilitating longitudinal monitoring of blood pressure outside conventional clinical settings. The wrist-based configuration requires appropriate positioning at heart level during measurement to ensure accuracy, and the device incorporates internal calibration and signal processing mechanisms to compensate for motion and positional variations within acceptable limits.

Participants allocated to the intervention group will be provided with the wearable device and instructed to wear it on the wrist continuously during waking hours, and where feasible during sleep. Blood pressure measurements will be taken at predefined intervals (e.g., multiple readings per day), either automatically or with participant initiation. Data will be recorded digitally and synchronized with a compatible smartphone application for storage and review. Participants will be followed up monthly over a three-month period. Wearable device readings will be reviewed for research purposes only and will not be used to make treatment decisions during the trial. Clinical decisions will be based on validated office BP and/or validated home BP readings, according to routine clinical care.

Participants will receive standardized training at baseline on:

• Proper positioning and wearing of the device

• Initiating blood pressure measurements

• Maintaining regular measurement schedules

• Charging and basic troubleshooting

Training will be delivered by trained research staff using a structured protocol. Written and visual guides will be provided. Study personnel will also be trained in device setup, and data retrieval procedures to ensure consistency.

Frequency of data recording • Wearable – participant-initiated measurements: Two sessions per day, with two readings 1–2 minutes apart at each session, on at least 3 days per week for 3 months. • Wearable – automatic measurements: Every 15 minutes during daytime and every 30 minutes at night during two designated 24-hour validation periods, at baseline and at 3 months.

Participants in the wearable device group will undergo standard 24-hour ambulatory blood pressure monitoring (ABPM) at two time points: the first within the first two weeks after commencement of the intervention and the second within the final two weeks of the 3-month intervention period.

4.Standard therapy/standard of care for the control arm Participants will continue their usual antihypertensive treatment and routine clinical care at NHSL. Treatment may be adjusted by the treating clinician according to routine practice and BP measurements. No standard therapy will be withheld because of participation in the study.

• Home BP group: Morning and evening, two readings per session, on at least 3 days per week for 3 months. • Office BP group: At routine clinic visits, generally every 4 weeks.


Inclusion criteria

• Age of 18 years or above

• Diagnosed hypertension for more than 6 months

• On two or fewer antihypertensive medications

• Baseline clinic blood pressure between 120/70 mmHg and 180/110 mmHg at screening

Additional requirements depending on study group:

• Wrist blood pressure monitoring group: Access to an electronic device compatible with the wrist blood pressure monitoring device (phone running Android 8.0/iOS 13.0 or later), ability to understand and operate the smartphone application used with the wearable device, and the standard ABPM device after training. Ability to use the smartphone application and ABPM device will be assessed after a standardised training session. Participants will be asked to demonstrate key steps, including opening the application, pairing/synchronising the wearable device, viewing/confirming a blood pressure reading, responding to reminders, and correctly wearing/starting the ABPM device. Participants who are able to perform these tasks independently or with minimal assistance after training will be included in the wrist blood pressure monitoring group.

• Home blood pressure monitoring group: ability to use a validated home blood pressure monitoring device after training. Ability to use the validated home blood pressure monitoring device will be assessed following a standardised training session. Participants will be required to demonstrate correct blood pressure measurement technique, including proper cuff placement, appropriate body positioning (seated, back supported, feet flat, arm at heart level), resting before measurement, and obtaining and recording a reading. Participants who are able to perform these steps correctly and independently (or with minimal prompting) after training will be included in the home blood pressure monitoring group.


Exclusion criteria

• Clinical evidence of hypertension-mediated target organ damage, including prior stroke or transient ischemic attack, ischemic heart disease or heart failure and chronic kidney disease (eGFR<60ml/min/1.73m2).

• Severely uncontrolled hypertension, defined as SBP greater than or equal to 180 mmHg or DBP greater than or equal to 110 mmHg at screening, requiring urgent clinical management

• Baseline clinic blood pressure below 120/70 mmHg, as the study is designed to assess improvement in blood pressure control among participants with suboptimal or borderline blood pressure control.

• Significant arrhythmias that may interfere with accurate blood pressure measurement

• Use of medications known to significantly affect blood pressure, other than anti-hypertensive medications.

• Severe chronic illness that may influence blood pressure control (e.g. advanced malignancy, severe liver disease)

• Pregnancy - different cardiovascular physiology



Primary outcome(s)

1.

Change in systolic blood pressure from baseline to 3 months -

At each clinic assessment, blood pressure will be measured in the seated position after at least 5 minutes of rest using a validated electronic blood pressure measuring device using an appropriately sized cuff following the standard protocol by a practising clinician at the medical clinic, trained on standard blood pressure measurement. Three readings will be taken 1–2 minutes apart, and the average of the last two readings will be used for analysis.

[

At baseline, at each monthly follow-up visit and at the end of three months.

]

Secondary outcome(s)

1.

Change in diastolic blood pressure from baseline to 3 months -

Diastolic blood pressure will be measured using a validated automated electronic blood pressure monitor, following a standardised blood pressure measurement protocol. At each assessment, three readings will be taken after adequate rest, and the average of the last two readings will be used for analysis.

[

At baseline, at each monthly follow-up visit and at the end of three months.

]
2.

Proportion achieving target blood pressure control <130/80 mmHg at 3 months -

Blood pressure control will be assessed using the clinic blood pressure measured at the month three follow-up visit. Participants with systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg will be categorised as having achieved target blood pressure control.

[

At the end of three months.

]
3.

Number and type of antihypertensive treatment modifications during follow-up -

Treatment modifications will be extracted from clinic records and participant medical records. These will include initiation of a new antihypertensive drug, discontinuation of treatment, dose escalation, dose reduction, or switching of drug class.

[

At each monthly follow-up visit.

]
4.

Number of scheduled and unscheduled hypertension-related clinical visits -

Scheduled clinic visits will be recorded from routine clinic attendance records. Unscheduled hypertension-related visits, including additional clinic visits, emergency visits, or hospital visits related to blood pressure control or antihypertensive treatment, will be recorded from medical records and participant self-report at each follow-up.

[

At each monthly follow-up visit.

]
5.

Medication adherence and adverse effects of intervention -

Medication adherence will be assessed using the brief medication adherence questionnaire and review of participant self-report at each follow-up visit. Current antihypertensive medications, missed doses, and reasons for non-adherence will be documented. Adverse effects related to the monitoring strategy will be assessed using a structured questionnaire at follow-up visits. These will include anxiety, discomfort, pain, skin irritation, sleep disturbance, or any other participant-reported problem related to device use or blood pressure monitoring.

[

At each monthly follow-up visit.

]
6.

Adherence to assigned blood pressure monitoring strategy -

Adherence will be assessed by comparing the number of completed blood pressure measurements with the number of expected scheduled measurements during the study period. For the wearable wrist blood pressure group, adherence will be assessed using device/app-recorded measurement logs. For the home blood pressure monitoring group, adherence will be assessed using participant blood pressure logbooks. For the office blood pressure monitoring group, adherence will be assessed using attendance at scheduled clinic visits and availability of office blood pressure measurements.

[

At each monthly follow-up visit.

]
7.

Any participant-reported anxiety, distress, inappropriate self-adjustment of medication, or healthcare contact triggered by wearable blood pressure readings will be documented as part of safety monitoring.

[

At each monthly follow-up visit

]
8.

Device accuracy and reliability outcome -

In the wearable wrist blood pressure group, wrist readings will be compared with 24-hour ABPM readings taken over corresponding time periods. Time-matched comparisons will be performed within ±5 minutes where feasible. Where exact matching is not possible, the nearest available reading within a predefined time window will be used. Accuracy will be assessed using mean difference (bias) between wearable wrist and ABPM readings, with 95% confidence intervals. Agreement will be assessed using Bland–Altman plots and 95% limits of agreement. Reliability/agreement will also be assessed using intraclass correlation coefficients. The proportion of wrist readings within ±5, ±10, and ±15 mmHg of matched ABPM readings will be calculated.

[

At each monthly follow-up visit

]
9.

Feasibility and implementation outcomes -

  1. Recruitment rate: number enrolled / number eligible.

  2. Consent rate: number consented / number invited.

  3. Retention rate: number completing 3-month follow-up / number enrolled.

  4. Protocol adherence: proportion completing required study procedures and follow- up visits.

  5. Device utilisation: frequency of wearable or home blood pressure monitor use during follow-up.

  6. Data completeness: proportion of expected blood pressure readings and follow-up data successfully collected.

[

At baseline, at each monthly clinic visit and at the end of the study period (3 months)

]
10.

Acceptability and usability outcomes - Acceptability and usability will be assessed at the end of follow-up using structured questionnaires with Likert-scale responses and qualitative in-depth interviews. Patient assessments will explore ease of use, comfort, understanding, satisfaction, perceived usefulness, willingness to continue use, and barriers to use. Clinician assessments will explore usefulness for clinical decision-making, feasibility within clinic workflow, perceived reliability, and barriers to routine implementation.

[

At each monthly clinic visit and at the end of the study period (3 months)

]
11.
  1. Sociodemographic variables - Age, sex, ethnicity, education level, occupation, income category, marital status, and area of residence will be collected using an interviewer-administered structured questionnaire at baseline.

  2. Anthropometric variables - Height will be measured using a stadiometer. Weight will be measured using a calibrated weighing scale. BMI will be calculated as weight in kilograms divided by height in metres squared. Waist circumference will be measured using a non-stretchable measuring tape at the standard anatomical midpoint, with the participant standing.

  3. Lifestyle variable - Physical activity will be assessed using the International Physical Activity Questionnaire–Short Form (IPAQ-SF). Physical activity will be categorised according to standard IPAQ scoring criteria.

  4. Clinical variables - Duration of hypertension, comorbidities, and other relevant clinical history will be collected using the structured questionnaire and verified from clinic records where available.

  5. Medication-related variables - Current antihypertensive medications, number of antihypertensive drugs, drug classes, dose, frequency, treatment changes, and other medications that may affect blood pressure will be recorded from clinic records, prescriptions, and participant self-report.

[

At each monthly clinic visit and at the end of the study period (3 months)

]

Target number/sample size

180 (60 in each arm)


Countries of recruitment

Sri Lanka


Anticipated start date

2026-12-01


Anticipated end date

2027-10-31


Date of first enrollment


Date of study completion


Recruitment status

Pending


Funding source

International Society of Hypertension


Regulatory approvals

Ethics Review Committee, Faculty of Medicine, University of Colombo



State of Ethics Review Approval


Status

Approved


Date of Approval

2026-06-18


Approval number

EC-26-079


Details of Ethics Review Committee

Name: Ethics Review Committee, Faculty of Medicine, University of Colombo
Institutional Address:Ethics Review Committee, Faculty of Medicine, University of Colombo, No.25, Kynsey Road, Colombo – 08, Sri Lanka.
Telephone:+94 112 695 300 ext: 240
Email: erc@med.cmb.ac.lk

Contact & Sponsor Information


Contact person for Scientific Queries/Principal Investigator

Prof. Priyanga Ranasinghe
Professor in Pharmacology
Department of Pharmacology, Faculty of Medicine, No.25, Po Box. 271, Kynsey Road, Colombo – 08, Sri Lanka

+94 763 237 722
+94 112 691 581
priyanga@pharm.cmb.ac.lk

Contact Person for Public Queries

Prof. Priyanga Ranasinghe
Professor in Pharmacology
Department of Pharmacology, Faculty of Medicine, No.25, Po Box. 271, Kynsey Road, Colombo – 08, Sri Lanka

+94 763 237 722
+94 112 691 581
priyanga@pharm.cmb.ac.lk


Primary study sponsor/organization

International Society of Hypertension
Member
International Society of hypertension 29 Gildredge Road Eastbourne East Sussex BN21 4RU United Kingdom
+44 (0)131 336 4203

secretariat@ish-world.com

Secondary study sponsor (If any)

None





Trial Completion details


Do the investigators plan to share identified individual clinical trial participant-level data (IPD)?

No


IPD sharing plan description


Study protocol available

Yes


Protocol version and date

1.1


Protocol URL


Results summary available

No


Date of posting results


Date of study completion


Final sample size


Date of first publication


Link to results


Brief summary of results